Australia markets open in 4 hours 33 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
303.45+2.81 (+0.93%)
As of 02:27PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 74.26B
Enterprise value 65.85B
Trailing P/E 23.44
Forward P/E 18.69
PEG ratio (5-yr expected) 0.39
Price/sales (ttm)8.96
Price/book (mrq)6.22
Enterprise value/revenue 7.89
Enterprise value/EBITDA 15.94

Trading information

Stock price history

Beta (5Y monthly) 0.45
52-week change 366.18%
S&P500 52-week change 3-13.12%
52-week high 3305.95
52-week low 3176.36
50-day moving average 3287.92
200-day moving average 3262.63

Share statistics

Avg vol (3-month) 31.38M
Avg vol (10-day) 31.52M
Shares outstanding 5256.46M
Implied shares outstanding 6N/A
Float 8255.86M
% held by insiders 10.23%
% held by institutions 194.36%
Shares short (14 Sept 2022) 42.89M
Short ratio (14 Sept 2022) 42.44
Short % of float (14 Sept 2022) 41.13%
Short % of shares outstanding (14 Sept 2022) 41.13%
Shares short (prior month 14 Aug 2022) 42.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022

Profitability

Profit margin 38.26%
Operating margin (ttm)37.59%

Management effectiveness

Return on assets (ttm)14.11%
Return on equity (ttm)30.24%

Income statement

Revenue (ttm)8.35B
Revenue per share (ttm)32.64
Quarterly revenue growth (yoy)22.50%
Gross profit (ttm)3.62B
EBITDA 3.28B
Net income avi to common (ttm)3.19B
Diluted EPS (ttm)12.69
Quarterly earnings growth (yoy)1,109.70%

Balance sheet

Total cash (mrq)9.25B
Total cash per share (mrq)36.08
Total debt (mrq)847.3M
Total debt/equity (mrq)7.10
Current ratio (mrq)4.50
Book value per share (mrq)46.61

Cash flow statement

Operating cash flow (ttm)4.02B
Levered free cash flow (ttm)2.52B